Cargando…

Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China

BACKGROUND: Traditional Chinese medicine (TCM) has a long history and its own characteristics in the treatment of allergic rhinitis. In this study, the efficacy and safety of patients with allergic rhinitis treated with Sanfeng Tongqiao Diwan were observed to support the clinical medication of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Haisheng, Luo, Jiaying, Ma, Jing, Liang, Zhiman, Dai, Jinyu, Wang, Wenxin, Zhong, Jinglin, Tian, Loushi, Sun, Baoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279765/
https://www.ncbi.nlm.nih.gov/pubmed/35845528
http://dx.doi.org/10.21037/atm-22-2768
_version_ 1784746473204744192
author Hu, Haisheng
Luo, Jiaying
Ma, Jing
Liang, Zhiman
Dai, Jinyu
Wang, Wenxin
Zhong, Jinglin
Tian, Loushi
Sun, Baoqing
author_facet Hu, Haisheng
Luo, Jiaying
Ma, Jing
Liang, Zhiman
Dai, Jinyu
Wang, Wenxin
Zhong, Jinglin
Tian, Loushi
Sun, Baoqing
author_sort Hu, Haisheng
collection PubMed
description BACKGROUND: Traditional Chinese medicine (TCM) has a long history and its own characteristics in the treatment of allergic rhinitis. In this study, the efficacy and safety of patients with allergic rhinitis treated with Sanfeng Tongqiao Diwan were observed to support the clinical medication of patients with allergic rhinitis. METHODS: A total of 61 patients with allergic rhinitis aged 12–70 years from the First Affiliated Hospital of Guangzhou Medical University were included in this study. All the patients were treated with Sanfeng Tongqiao Diwan for a period of 7 days. Return visits were carried out 24 hours after the first medication, the 4th day of medication, and the 7th day of medication, during which the efficacy and safety were assessed. RESULTS: The effective rates of Sanfeng Tongqiao Diwan at 24 hours, 4 days, and 7 days were 49.2%, 60.7%, and 65.6%, respectively. Comparing the severity of various symptoms after treatment to baseline, significant differences were found in nasal secretion (2.95±0.67 vs. 2.26±1.30, P<0.001), stuffy nose (5.66±2.95 vs. 3.34±2.57, P<0.001), mucosa congestion (7.08±1.82 vs. 4.23±2.28, P<0.001), running nose (5.21±1.81 vs. 2.90±1.89, P<0.001), and sneezing (3.00±0 vs. 1.92±1.45, P<0.001). The full symptom scores showed progressive decline during treatment, measuring 20.21±5.13 at baseline and 12.02±6.47 at 7 days (P<0.001). Compared to the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score of 64.61±30.27 at baseline, statistical significance (P<0.001) was found at 24 hours, 4 days, and 7 days, measuring 43.11±28.01, 40.74±28.6, and 39.97±40.48, respectively. The incidence rate of adverse events (AEs) was 3.3% (2/61), with no serious AEs. CONCLUSIONS: In this study, the use of Sanfeng Tongqiao Diwan is effective in the treatment of allergic rhinitis patients, especially in patients with severe symptoms. Although the treatment system of TCM is different from that of Western medicine, the application of TCM will provide a new direction for the treatment of chronic diseases. Follow-up studies with an increased sample size are required for verification.
format Online
Article
Text
id pubmed-9279765
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-92797652022-07-15 Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China Hu, Haisheng Luo, Jiaying Ma, Jing Liang, Zhiman Dai, Jinyu Wang, Wenxin Zhong, Jinglin Tian, Loushi Sun, Baoqing Ann Transl Med Original Article BACKGROUND: Traditional Chinese medicine (TCM) has a long history and its own characteristics in the treatment of allergic rhinitis. In this study, the efficacy and safety of patients with allergic rhinitis treated with Sanfeng Tongqiao Diwan were observed to support the clinical medication of patients with allergic rhinitis. METHODS: A total of 61 patients with allergic rhinitis aged 12–70 years from the First Affiliated Hospital of Guangzhou Medical University were included in this study. All the patients were treated with Sanfeng Tongqiao Diwan for a period of 7 days. Return visits were carried out 24 hours after the first medication, the 4th day of medication, and the 7th day of medication, during which the efficacy and safety were assessed. RESULTS: The effective rates of Sanfeng Tongqiao Diwan at 24 hours, 4 days, and 7 days were 49.2%, 60.7%, and 65.6%, respectively. Comparing the severity of various symptoms after treatment to baseline, significant differences were found in nasal secretion (2.95±0.67 vs. 2.26±1.30, P<0.001), stuffy nose (5.66±2.95 vs. 3.34±2.57, P<0.001), mucosa congestion (7.08±1.82 vs. 4.23±2.28, P<0.001), running nose (5.21±1.81 vs. 2.90±1.89, P<0.001), and sneezing (3.00±0 vs. 1.92±1.45, P<0.001). The full symptom scores showed progressive decline during treatment, measuring 20.21±5.13 at baseline and 12.02±6.47 at 7 days (P<0.001). Compared to the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score of 64.61±30.27 at baseline, statistical significance (P<0.001) was found at 24 hours, 4 days, and 7 days, measuring 43.11±28.01, 40.74±28.6, and 39.97±40.48, respectively. The incidence rate of adverse events (AEs) was 3.3% (2/61), with no serious AEs. CONCLUSIONS: In this study, the use of Sanfeng Tongqiao Diwan is effective in the treatment of allergic rhinitis patients, especially in patients with severe symptoms. Although the treatment system of TCM is different from that of Western medicine, the application of TCM will provide a new direction for the treatment of chronic diseases. Follow-up studies with an increased sample size are required for verification. AME Publishing Company 2022-06 /pmc/articles/PMC9279765/ /pubmed/35845528 http://dx.doi.org/10.21037/atm-22-2768 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Hu, Haisheng
Luo, Jiaying
Ma, Jing
Liang, Zhiman
Dai, Jinyu
Wang, Wenxin
Zhong, Jinglin
Tian, Loushi
Sun, Baoqing
Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China
title Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China
title_full Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China
title_fullStr Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China
title_full_unstemmed Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China
title_short Efficacy and safety of Sanfeng Tongqiao Diwan in patients with allergic rhinitis: a single-arm clinical trial in China
title_sort efficacy and safety of sanfeng tongqiao diwan in patients with allergic rhinitis: a single-arm clinical trial in china
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279765/
https://www.ncbi.nlm.nih.gov/pubmed/35845528
http://dx.doi.org/10.21037/atm-22-2768
work_keys_str_mv AT huhaisheng efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT luojiaying efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT majing efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT liangzhiman efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT daijinyu efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT wangwenxin efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT zhongjinglin efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT tianloushi efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina
AT sunbaoqing efficacyandsafetyofsanfengtongqiaodiwaninpatientswithallergicrhinitisasinglearmclinicaltrialinchina